Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone for Prevention of Post-stroke Epilepsy
NCT05987397Phase 4Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of idebenone in epilepsy (3 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: The proportion of patients with epilepsy after stroke at 48 weeks. Started Jul 2023; status: recruiting.
02
Drugs
idebenone
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05987397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987397.